Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Anakinra (Kineret®)
Anakinra · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| placebo | PLACEBO_COMPARATOR | - |
| anakinra | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Anakinra (Kineret®) | DRUG | - |
| anakinra | DRUG | - |
| pegsunercept | DRUG | - |
| Placebo | DRUG | placebo |
Inclusion Criteria: - Subjects diagnosed with RA as determined by American College of Rheumatology (ACR) criteria with a disease duration of at least 24 weeks prior to enrollment - Active RA at screening as defined by EITHER: (1) At least 6 swollen joints (using a 66 joint count) and at least 6 tend...
Top 20 of 31 competitors
Anakinra is used for the treatment of Juvenile Chronic Arthritis and Rheumatoid Arthritis. It is an immunology therapy developed by Amgen Inc. (ticker: AMGN) and is also known by the brand name Kineret. The drug is currently in Phase 2 clinical development for these indications.
Anakinra targets the interleukin-1 receptor type 1 (IL1R1). It acts as an antagonist at this receptor, blocking interleukin-1 signaling. This mechanism is intended to reduce inflammation associated with Juvenile Chronic Arthritis and Rheumatoid Arthritis.
Anakinra is developed by Amgen Inc., which trades under the ticker symbol AMGN. The company is responsible for the clinical development of the drug, also known as Kineret, for immunology indications including Juvenile Chronic Arthritis and Rheumatoid Arthritis.
Anakinra is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA for the indications described. The development program includes completed Phase 2 and Phase 3 trials in Rheumatoid Arthritis and Juvenile Chronic Arthritis.
Anakinra has been studied in completed clinical trials including NCT00117091, a Phase 3 trial in Rheumatoid Arthritis; NCT00037700, a Phase 2 trial in Rheumatoid Arthritis; and NCT00037648, a Phase 2 trial in Juvenile Chronic Arthritis with 86 participants. No active trials are currently listed.
Yes, Anakinra is also known by the brand name Kineret. Kineret is the registered trademark name for the same drug. Both names refer to the interleukin-1 receptor antagonist developed by Amgen Inc. for immunology indications.